Approxima was founded in 2020 and is an early stage MedTech startup, spin-off from Politecnico di Milano. The mission of the company is to develop a minimally invasive tricuspid valve repair system to treat patients with tricuspid valve regurgitation. The system allows reshaping of the right ventricle directly counteracting the right heart dilation. The device is intended to be implanted in the heart of a patient via minimally invasive procedure guided by medical imaging under beating heart conditions.
The company is conducting preclinical feasibility phase studies to demonstrate in-vivo feasibility, efficacy, and safety.
The offices of the company are located in Milan, Italy, and the company is virtually incubated at Bioindustry Park Silvano Fumero SpA.